Abbott Laboratories (ABT)vsGlobus Medical (GMED)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
GMED
Globus Medical
$87.35
+1.28%
HEALTHCARE · Cap: $11.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 1408% more annual revenue ($44.33B vs $2.94B). GMED leads profitability with a 18.3% profit margin vs 14.7%. ABT appears more attractively valued with a PEG of 1.52. GMED earns a higher WallStSmart Score of 74/100 (B).
ABT
Buy51
out of 100
Grade: C-
GMED
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Margin of Safety
+51.9%
Fair Value
$183.46
Current Price
$87.35
$96.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 24.4%
Revenue surging 25.7% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
Expensive relative to growth rate
4.4% earnings growth
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : GMED
The strongest argument for GMED centers on Altman Z-Score, Price/Book, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 24.4%. Revenue growth of 25.7% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : GMED
The primary concerns for GMED are PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ABT profiles as a value stock while GMED is a growth play — different risk/reward profiles.
GMED carries more volatility with a beta of 1.07 — expect wider price swings.
GMED is growing revenue faster at 25.7% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Bottom Line
GMED scores higher overall (74/100 vs 51/100), backed by strong 18.3% margins and 25.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Globus Medical
HEALTHCARE · MEDICAL DEVICES · USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?